• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

华法林的药理学、临床管理及老年人出血风险评估

Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly.

作者信息

Jacobs Laurie G

机构信息

Albert Einstein College of Medicine and Montefiore Medical Center, 111 East 210 Street, Bronx, NY 10467, USA.

出版信息

Cardiol Clin. 2008 May;26(2):157-67, v. doi: 10.1016/j.ccl.2007.12.010.

DOI:10.1016/j.ccl.2007.12.010
PMID:18406992
Abstract

Warfarin, a vitamin K antagonist, is currently the most extensively used oral anticoagulant world-wide. It is prescribed for a variety of indications and has undergone extensive clinical study. Still, despite wide usage and considerable accumulated data from clinical trials demonstrating efficacy for a variety of thrombotic and thromboembolic conditions, warfarin is underutilized because its management is complex for both patients and physicians. However, despite these limitations, warfarin can be managed with relative safety, even in an elderly population.

摘要

华法林是一种维生素K拮抗剂,目前是全球使用最广泛的口服抗凝剂。它被用于多种适应症,并且已经经历了广泛的临床研究。尽管华法林使用广泛,且临床试验积累了大量数据证明其对多种血栓形成和血栓栓塞性疾病有效,但由于其对患者和医生而言管理复杂,所以未得到充分利用。然而,尽管有这些局限性,即使在老年人群中,华法林也可以相对安全地管理。

相似文献

1
Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly.华法林的药理学、临床管理及老年人出血风险评估
Cardiol Clin. 2008 May;26(2):157-67, v. doi: 10.1016/j.ccl.2007.12.010.
2
Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly.华法林的药理学、临床管理及老年人出血风险评估
Clin Geriatr Med. 2006 Feb;22(1):17-32, vii-viii. doi: 10.1016/j.cger.2005.09.001.
3
Warfarin therapy: evolving strategies in anticoagulation.华法林治疗:抗凝治疗策略的演变
Am Fam Physician. 1999 Feb 1;59(3):635-46.
4
Correction of coagulopathy in warfarin associated cerebral hemorrhage.华法林相关脑出血中凝血障碍的纠正
Curr Opin Crit Care. 2009 Apr;15(2):87-92. doi: 10.1097/MCC.0b013e3283269e4d.
5
Multivitamin supplements may affect warfarin anticoagulation in susceptible patients.
Ann Pharmacother. 2003 Nov;37(11):1603-6. doi: 10.1345/aph.1D102.
6
[Prothrombin complex concentrate good in warfarin induced hemorrhage. Quick reversal--plasma should be avoided].[凝血酶原复合物浓缩剂对华法林引起的出血有效。快速逆转——应避免使用血浆]
Lakartidningen. 2009;106(37):2278, 2280-1.
7
Bleeding rates in elderly patients on vitamin K antagonist therapy for nonvalvular atrial fibrillation.老年患者接受维生素K拮抗剂治疗非瓣膜性心房颤动时的出血率
Blood Coagul Fibrinolysis. 2009 Jul;20(5):392-3. doi: 10.1097/MBC.0b013e32832aec47.
8
Warfarin prevalence, indications for use and haemorrhagic events.
Ir Med J. 2007 Mar;100(3):402-4.
9
Vitamin K and thrombosis.
Vitam Horm. 2008;78:265-79. doi: 10.1016/S0083-6729(07)00013-1.
10
[Hemorrhagic complications during warfarin treatment].[华法林治疗期间的出血并发症]
Vnitr Lek. 2006 Mar;52 Suppl 1:79-91.

引用本文的文献

1
The association between warfarin usage and international normalized ratio increase: systematic analysis of FDA Adverse Event Reporting System (FAERS).华法林使用与国际标准化比值升高之间的关联:美国食品药品监督管理局不良事件报告系统(FAERS)的系统分析
J Cardiovasc Aging. 2023 Oct;3(4). doi: 10.20517/jca.2023.33. Epub 2023 Oct 17.
2
Challenges of Anticoagulant Therapy in Atrial Fibrillation-Focus on Gastrointestinal Bleeding.房颤抗凝治疗面临的挑战-关注胃肠道出血。
Int J Mol Sci. 2023 Apr 7;24(8):6879. doi: 10.3390/ijms24086879.
3
Antithrombotic therapy for secondary prevention of unprovoked venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials.
抗血栓治疗在特发性静脉血栓栓塞症二级预防中的应用:随机对照试验的系统评价和网络荟萃分析。
Ann Med. 2022 Dec;54(1):253-261. doi: 10.1080/07853890.2022.2026002.
4
Standardized warfarin monitoring decreases adverse drug reactions.标准化华法林监测可减少药物不良反应。
BMC Fam Pract. 2019 Nov 7;20(1):151. doi: 10.1186/s12875-019-1041-5.
5
Rapid and substantial increases in anticoagulant use and expenditure in Australia following the introduction of new types of oral anticoagulants.新型口服抗凝药物上市后,澳大利亚的抗凝药物使用量和支出迅速大幅增加。
PLoS One. 2018 Dec 6;13(12):e0208824. doi: 10.1371/journal.pone.0208824. eCollection 2018.
6
Bleeding events attributable to concurrent use of warfarin and other medications in high-risk elderly: meta-analysis and Italian population-based investigation.高危老年患者同时使用华法林和其他药物引起的出血事件:荟萃分析和意大利基于人群的调查。
Eur J Clin Pharmacol. 2018 Aug;74(8):1061-1070. doi: 10.1007/s00228-018-2467-8. Epub 2018 May 7.
7
Phenotyping of CYP 4501A2 Activity by Total Overnight Salivary Caffeine Assessment (TOSCA) in Patients on Warfarin Treatment: A Cross-Sectional Study.华法林治疗患者中通过总夜间唾液咖啡因评估(TOSCA)对CYP 4501A2活性进行表型分析:一项横断面研究。
Clin Appl Thromb Hemost. 2018 Sep;24(6):928-935. doi: 10.1177/1076029617733040. Epub 2017 Oct 9.
8
Peptic ulcer diseases: genetics, mechanism, and therapies.消化性溃疡疾病:遗传学、机制与治疗
Biomed Res Int. 2014;2014:898349. doi: 10.1155/2014/898349. Epub 2014 Dec 28.
9
A review of the safety of anticoagulants in older people using the medicines management pathway: weighing the benefits against the risks.老年人使用药物管理途径的抗凝剂安全性综述:权衡利弊。
Ther Adv Drug Saf. 2011 Apr;2(2):45-58. doi: 10.1177/2042098611400495.
10
Gastrointestinal hemorrhage in warfarin anticoagulated patients: incidence, risk factor, management, and outcome.华法林抗凝治疗患者的胃肠道出血:发生率、危险因素、管理及结局
Biomed Res Int. 2014;2014:463767. doi: 10.1155/2014/463767. Epub 2014 May 29.